Vivos Therapeutics Inc
NASDAQ:VVOS
Vivos Therapeutics Inc
NASDAQ:VVOS
Price:
1.45
USD
-1.36%
Market Cap:
$13.7m
Income Statement
Earnings Waterfall
Vivos Therapeutics Inc
Vivos Therapeutics Inc
Income Statement
Vivos Therapeutics Inc
Vivos Therapeutics Inc
Currency: USD
| Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||||||
| Interest Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Revenue |
13
N/A
|
10
-23%
|
15
+45%
|
16
+9%
|
17
+7%
|
17
+1%
|
17
-2%
|
16
-2%
|
16
-3%
|
16
+1%
|
15
-5%
|
15
-6%
|
14
-5%
|
13
-3%
|
14
+5%
|
15
+4%
|
15
+3%
|
15
-3%
|
14
-2%
|
17
+20%
|
|
| Gross Profit | |||||||||||||||||||||
| Cost of Revenue |
(3)
|
(2)
|
(3)
|
(4)
|
(4)
|
(5)
|
(5)
|
(6)
|
(6)
|
(6)
|
(6)
|
(6)
|
(6)
|
(5)
|
(6)
|
(6)
|
(6)
|
(6)
|
(6)
|
(8)
|
|
| Gross Profit |
10
N/A
|
8
-24%
|
12
+45%
|
12
+5%
|
13
+3%
|
12
-1%
|
11
-8%
|
11
-6%
|
10
-7%
|
10
-2%
|
9
-5%
|
9
-6%
|
8
-5%
|
8
-5%
|
8
+7%
|
9
+5%
|
9
+2%
|
9
-5%
|
8
-6%
|
10
+20%
|
|
| Operating Income | |||||||||||||||||||||
| Operating Expenses |
(22)
|
(19)
|
(27)
|
(31)
|
(32)
|
(35)
|
(37)
|
(36)
|
(35)
|
(33)
|
(30)
|
(28)
|
(26)
|
(24)
|
(22)
|
(21)
|
(20)
|
(20)
|
(22)
|
(26)
|
|
| Selling, General & Administrative |
(18)
|
(16)
|
(23)
|
(27)
|
(31)
|
(34)
|
(36)
|
(36)
|
(34)
|
(33)
|
(30)
|
(27)
|
(25)
|
(23)
|
(21)
|
(21)
|
(20)
|
(19)
|
(22)
|
(25)
|
|
| Depreciation & Amortization |
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
|
| Other Operating Expenses |
(3)
|
(3)
|
(3)
|
(3)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Operating Income |
(12)
N/A
|
(11)
+5%
|
(16)
-35%
|
(19)
-24%
|
(19)
-1%
|
(23)
-16%
|
(26)
-13%
|
(25)
+0%
|
(25)
+2%
|
(23)
+6%
|
(21)
+10%
|
(19)
+9%
|
(17)
+9%
|
(16)
+7%
|
(13)
+16%
|
(13)
+7%
|
(11)
+11%
|
(11)
-1%
|
(14)
-26%
|
(16)
-15%
|
|
| Pre-Tax Income | |||||||||||||||||||||
| Interest Income Expense |
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
(1)
|
0
|
0
|
0
|
1
|
0
|
0
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Other Income |
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
3
|
2
|
4
|
4
|
0
|
1
|
(0)
|
0
|
0
|
(0)
|
(1)
|
|
| Pre-Tax Income |
(12)
N/A
|
(11)
+5%
|
(16)
-35%
|
(19)
-23%
|
(20)
-6%
|
(22)
-9%
|
(25)
-13%
|
(25)
+0%
|
(24)
+5%
|
(20)
+15%
|
(19)
+7%
|
(15)
+18%
|
(14)
+12%
|
(16)
-15%
|
(12)
+23%
|
(13)
-4%
|
(11)
+11%
|
(11)
-1%
|
(14)
-27%
|
(17)
-19%
|
|
| Net Income | |||||||||||||||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Income from Continuing Operations |
(12)
|
(11)
|
(16)
|
(19)
|
(20)
|
(22)
|
(25)
|
(25)
|
(24)
|
(20)
|
(19)
|
(15)
|
(14)
|
(16)
|
(12)
|
(13)
|
(11)
|
(11)
|
(14)
|
(17)
|
|
| Net Income (Common) |
(12)
N/A
|
(11)
+5%
|
(16)
-35%
|
(19)
-23%
|
(20)
-6%
|
(22)
-9%
|
(25)
-13%
|
(25)
+0%
|
(24)
+5%
|
(20)
+15%
|
(19)
+7%
|
(15)
+18%
|
(14)
+12%
|
(16)
-15%
|
(12)
+23%
|
(13)
-4%
|
(11)
+11%
|
(11)
-1%
|
(14)
-27%
|
(17)
-19%
|
|
| EPS (Diluted) |
-16.52
N/A
|
-15.69
+5%
|
-18.67
-19%
|
-23.06
-24%
|
-23.89
-4%
|
-26.12
-9%
|
-29.6
-13%
|
-29.57
+0%
|
-25.92
+12%
|
-20.41
+21%
|
-15.62
+23%
|
-12.84
+18%
|
-11.14
+13%
|
-6.77
+39%
|
-3.72
+45%
|
-1.89
+49%
|
-2.22
-17%
|
-1.3
+41%
|
-1.57
-21%
|
-1.56
+1%
|
|
Switch to:
Switch to:
See Also
Discover More
